MADISON, Wis.--(BUSINESS WIRE)--Lucigen Corporation announces it has signed a global agreement with Illumina, Inc. for Lucigen to be the sole distributor of Epicentre Technologies’ genomics kits, enzymes and ancillary reagents. Products covered by this new agreement are in addition to the select Epicentre products that were licensed and transferred to Lucigen for manufacture and distribution in December 2016.
Effective immediately, Lucigen Corporation will distribute the complete Epicentre product portfolio.
Epicentre Technologies, known for its genomics and transcriptomics products for gene expression, cloning, and in vitro transcription, was acquired by Illumina in 2011.
Lucigen manufactures and supplies products that advance research in the fields of synthetic biology, next generation sequencing, genetic amplification, and protein expression.
“We are excited for Lucigen to expand its Epicentre product offerings,” said Mark Van Oene, Chief Commercial Officer for Illumina. “Lucigen has been a tremendous partner to Illumina and this agreement will continue to benefit scientists by delivering a full portfolio of great products.”
“Illumina shares our commitment to serve scientists worldwide with high quality products that enable scientific breakthroughs. Providing a single-vendor solution gives life science professionals easy and seamless access to these products. The incorporation of products from the Epicentre portfolio, combined with Lucigen’s portfolio of genomics products, will help scientists accelerate and simplify their research,” stated Ralph Kauten, CEO of Lucigen.
Lucigen Corporation is working to improve people’s lives by providing quality products and services to life science and healthcare professionals. Lucigen provides biomedical research products and services to customers worldwide, all under an ISO 13485 compliant quality system. To learn more, visit www.lucigen.com and follow @lucigen.